Evolocumab, a PCSK9 inhibitor, protects human endothelial cells against HO-induced oxidative stress.

Context: Recent surveys have shown an association between proprotein convertase subtilisin/kexin type 9 (PCSK9) and oxidative stress.

Objective: In this investigation, the effect of evolocumab an anti-PCSK9 antibody was assessed against oxidative damage caused by hydrogen peroxide (HO) in human umbilical vein endothelial cells (HUVEC).

Material And Methods: Viability of HUVEC was measured by MTT assay.